- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07460739
Efficacité d'une application smartphone d'autogestion pour améliorer les compétences de sécurité chez les patients atteints d'arthrite inflammatoire (RHUMATOSMART)
Efficacité d'une application smartphone d'autogestion pour promouvoir les compétences de sécurité des patients atteints d'arthrite inflammatoire traités par des médicaments antirhumatismaux
Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis. These include conventional DMARDs such as methotrexate, as well as targeted DMARDs (tDMARDs), i.e., biological agents (bDMARDs) like anti-TNF alpha and JAK inhibitors. Patients treated with tDMARDs face a risk of adverse effects, including an increased risk of infections. Therapeutic patient education has been shown to help patients develop safety skills, but its effectiveness is only short-term.
Mobile health applications are increasingly used by patients to manage their health.
The French Society of Rheumatology (SFR) has developed a smartphone self-management application aimed at supporting people with inflammatory arthritis in managing their treatments, symptoms, and information needs. It provides advice on lifestyle and daily living, promotes treatment adherence, and enables self-assessment of disease status. The app includes seven features: a safety checklist before treatment administration, daily life aids based on French academic recommendations, treatment reminders, self-assessment of overall well-being, disease monitoring (pain, fatigue, patient global assessment of disease activity), periodic advisory messages, and a diary.
The application is not a medical device; collected data are stored on the user's smartphone. Patient data are not directly shared with physicians. Patients can use the app during consultations or share screenshots with their doctors. The app is more widely used and has a longer lifespan than most available apps, but its impact on patients still needs evaluation in a randomized controlled trial.
The primary hypothesis of the study is that using the app will improve safety skills in patients with inflammatory arthritis treated with tDMARDs compared to usual care, including access to the SFR patient information website.
The secondary hypothesis is that using the app will improve patient adherence and the patient-rheumatologist relationship.
Objectives : To determine whether the mobile application improves patients' ability to acquire safety-related skills in the daily use of targeted disease-modifying antirheumatic drugs (tDMARDs), compared to usual care, including access to an informational website for patients.
The primary outcome will be the change in the BioSecure questionnaire score at 6 months after inclusion, comparing the group using the mobile application with the group using the informational website.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Rheumatoid arthritis (RA) and spondyloarthritis (SpA) including psoriatic arthritis (PsA) represent painful chronic conditions impairing quality of life and work capacities. Disease-modifying anti-rheumatic drugs (DMARDs) are used to control inflammatory Arthritis (IA) disease activity, reduce functional disability and improve prognosis. They include conventional DMARDS (cDMARDs) such as methotrexate, targeted DMARDs (tDMARDs) i.e biologic agents (bDMARDs) such as tumor necrosis factor (TNF) alpha blockers, and Janus-kinase inhibitors (JAKi). The number of DMARDs is increasing (more than 15 DMARDs in France) and have a wide variety of targets and modes of administration . Patients treated by DMARDs are at risk of adverse events, including excess risk of infection, noted more in RA than SpA , in particular because of co-medication with glucocorticoids and/or high disease activity. Measures patients can take to decrease these risks include vaccinations , self-referral and DMARD interruption in some situations such as surgery, dental care or pregnancy, which patients need to discuss with health professionals. A nurse-led patient education has been shown to be effective in promoting safety skills of patients treated by biologics but education is not routinely provided in all rheumatology centres. Moreover, patient education is effective in the short term only, not exceeding 6 months .
Mobile health applications (mhealth apps) have undergone significant development in recent years and are of increasing interest and usefulness to help patients manage their chronic inflammatory arthritis (IA) . With reference to the well-established definition of self-management . that is, "the ability of the individual to manage symptoms, treatment, lifestyle changes and psychosocial and cultural consequences of health conditions", Apps may be appropriate tools for self-management such as medications management, problem-solving, and care coordination or to offer a more holistic approach . However, an app providing information to help patients be more aware of their medications in daily life and adopt appropriate behaviours with risk situations had not been addressed in IA.
In this context, the French Society of Rheumatology ( SFR) developed a self-management smartphone app, with the objective of helping IA people with their treatments, symptoms, and information needs, provide healthy lifestyle and daily life messages and promote adherence to medication and disease self-assessment . The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary. The app is not a medical device, data collected are stored within the user's smartphone. Patients' data are not to be directly communicated to the physicians, but patients can make screenshots of their app to communicate with their physician. The app was installed 20,500 times from September 2017 to October 2020 (nowadays 30,000 downloads), with 4300 regular current users. Scores were 4.4/5 stars at Android and iOS stores . The SFR app is the first published app with respect to medication management, all the more in France where very few health apps are available. Apart from SFR app, only one app has been published on medication management, tested on 85 patients . The SFR app is more widely used and has a longer lifespan than most apps available in IA: in the studies by EULAR, 75% people had stopped using m-health apps after 3 months for rheumatic and musculoskeletal diseases and only 5% of these apps were still available 2 years after their launch . Assessment of the impact of the SFR app is important since patients are more likely to download and use the app if it has a proven benefit and 2/3 of patients would use it if recommended by their physicians . Therefore, the impact of SFR app needs to be evaluated in a randomised controlled trial.
The first hypothesis of the study is that the use of the SFR app would promote safety skills of patients with IA treated with DMARDs, compared with usual care including access to a SFR patient information website.
The secondary hypothesis is that the use of the SFR app would promote adherence to tDMARDs and patient-rheumatologist's relationship.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Catherine BEAUVAIS, Medical Doctor
- Numéro de téléphone: +33149282520
- E-mail: catherine.beauvais@aphp.fr
Lieux d'étude
-
-
-
Paris, France, 75012
- Recrutement
- Rheumatology Hopital Saint Antoine
-
Contact:
- Catherine BEAUVAIS, Medical doctor
- Numéro de téléphone: +33149282520
- E-mail: catherine.beauvais@aphp.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age between 18 and 75 years
- Diagnosis of rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria of the American College of Rheumatology, or axial or peripheral spondyloarthritis (SpA) according to the 2009 ASAS criteria of the Assessment of SpondyloArthritis International Society, or psoriatic arthritis according to the 2009 CASPAR criteria.
- Undergoing a treatment change to a tDMARD (biologic or JAK inhibitor) available in the SFR application.
- No therapeutic education on tDMARDs in the past two years.
- Ability to use a smartphone application.
- Ability to use a website.
- Ability to complete a questionnaire.
- Signed informed consent for the study.
- Covered by social security or entitled to social protection.
Exclusion Criteria:
- Any condition that may affect comprehension or treatment adherence (chronic alcoholism, language barrier, severe psychiatric disorders, cognitive impairment).
- Planned treatment with intravenous bDMARDs in the upcoming year.
- Patients who have already downloaded self-management applications for their rheumatic disease.
- Patients enrolled in a therapeutic education program: face-to-face education by a nurse or healthcare professional, or group education.
- Patients who have already received therapeutic education on targeted DMARDs in the past two years: face-to-face education by a nurse or healthcare professional, or group education.
- Participation in another interventional clinical trial
- Pregnant or breast-feeding woman
- Individual under legal protection (tutorship or guardianship) or deprived of freedom
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Mobile Application
Patients in the intervention group will upload the SFR app |
The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary. |
|
Aucune intervention: information web site
Patients of both group willreceive a link that will give them access to SRF web site |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
safety skills regarding the use of tDMARDS
Délai: 6 month
|
safety skills regarding the use of tDMARDS will be assessed by the change of the updated BioSecure questionnaire score at 6 months from baseline in the SFR mobile app group versus the control group. The scores ranges from 0 to 50. A higher scores represents higher safety skills. |
6 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adherence to tDMARDs
Délai: 6 month
|
Adherence to tDMARDs assessed by the CQR5 questionnaire score (rate of adherent patients). The scores ranges from 4 to 20, with a high score indicating better adherence. |
6 month
|
|
patient-rheumatologist communication
Délai: 6 month
|
Patient-rheumatologist communication assessed by the PEPPI-5 questionnaire score (Perceived Efficacy in Patient-Physician Interactions). The scores ranges from 0-50; higher scores represent higher perceived self-efficacy in patient-physician interactions. |
6 month
|
|
confidence in taking care of one's health
Délai: 6 month
|
Health confidence assessed by the HCS questionnaire (Health confidence score). The scores ranges from 0 to 12. Higher score represents greater health confidence. |
6 month
|
|
Impact on disease including coping to disease.
Délai: 6 month
|
Impact of disease assessed by the RAID questionnaire score (rheumatoid arthritis impact of disease). |
6 month
|
|
Disease activity for rheumatoid arthritis
Délai: 6 months
|
Disease activity assessed by the RADAI (Rheumatoid Arthritis Disease Activity Index), The scores ranges from 0-48, higher score meaning higher disease activity |
6 months
|
|
Disease activity for axial spondyloarthritis
Délai: 6 months
|
Disease activity assessed by the BASDAI (Bath Ankylosing Spondylitis Disease activity). The scores ranges from 0 to 10, higher score meaning higher disease activity. |
6 months
|
|
Disease activity for psoriatic arthritis
Délai: 6 months
|
Disease activity assessed by SASPA (Stockerau Activity Score for Psoriatic Arthritis). The scores ranges from 0 to 5, higher score meaning higher disease activity. |
6 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Catherine BEAUVAIS, Medical Doctor, Assistance Publique - Hôpitaux de Paris
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- APHP241727
- IDRCB 2025-A01504-45 (Autre identifiant: ANSM)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .